Fermatron C synovial fluid prosthesis solution 2.3%, No. 1

Intra-articular injection of Fermatron C can only be performed by a medical professional who has undergone special training in the procedure for intra-articular injections. Fermatron C is produced in the form of a single dose of the drug, intended only for a single administration in the course of treatment.

The scheme of drug administration is a single injection of 3.0 ml Fermatron C, contained in one syringe, into the affected synovial space.

Before performing the injection, it is necessary to wipe the skin at the injection site with an antiseptic and allow it to dry. If there is an articular effusion, it is necessary to remove the fluid from it before the Fermatron C injection. Insert Fermatron C only into the articular cavity. When injecting into the hip joint, ensure accurate needle placement and insertion using fluoroscopic or ultrasound guidance.

When inserting a needle, especially for injections into the hip joint, the use of local anesthesia is recommended. Intra-articular effusion should be removed before injection of Fermatron C. To remove intra-articular effusion and intra-articular injection of Fermatron C, the same needle should be used.

The contents of the syringe are sterile and must be injected using a sterile, appropriately sized needle (18 to 21G). The syringe has a Luer Lok Щ (6%) connector to securely attach the needle to the syringe. After use, the syringe and needle must be disposed of

Sodium hyaluronate, mg / ml - 20.0 - 25.0

Sodium chloride, mg / ml - 7.8 - 9.0

Phosphates, mg / ml - 0.15-0.25

Do not administer if there is inflammation or signs of skin disease at the injection site.

Do not use in patients with known hypersensitivity to sodium hyaluronate.

pharmachologic effect

Fermathron C Synovial fluid prosthesis:

• restores the viscoelastic and protective properties of the joint fluid;

• reduces inflammatory reactions;

• eliminates pain syndrome;

• increases joint mobility;

• restores homeostasis in cartilage;

• stimulates the synthesis of hyaluronic acid;

• indicated at any stage of osteoarthritis and after arthroscopic interventions;

• clinically reliable result after the fourth injection;

• injected intra-articular with an interval of 7 days;

• long-term effect and absence of side effects;

• the only contraindication when using Fermathron: the presence of infection in the injection area.

Application during pregnancy and lactation

The safety of using Fermatron plus during pregnancy and lactation has not been established.

Prescribing the drug during pregnancy and lactation at the discretion of the orthopedic surgeon.

special instructions

Do not use if the washing packaging is damaged.

Sodium hyaluronate is obtained by fermentation of Streptococcus equi bacteria and is thoroughly purified.

However, the physician should consider the immunological effects and potential risks associated with the injection of any biological substances.

Sterile product for single use only.

Follow instructions for safe use and disposal of needles.

In case of injury, consult a doctor immediately. Not intended for children

Side effects

• With intra-articular administration, temporary passing pain and swelling are possible.

• In patients with inflammatory osteoarthritis, after administration of the drug, inflammation of the synovial joint may temporarily increase.

• In rare cases, an inflammatory reaction is possible, which may or may not be associated with the introduction of Fermatron.

Drug interactions

The compatibility of the simultaneous intra-articular administration of the drug Fermatron plus with other substances has not been tested.